Expression of cancer-testis antigen in multiple myeloma

Abstract

Recently, the immunotherapy has been highlighted among cancer treatments. Cancer-testis antigen (CTA) has been studied in a variety of solid tumors because of its specific expression in tumors, and testis, ovary and placenta tissues, but not in other normal tissues. In order to provide a new approach for multiple myeloma (MM) immunotherapy, we examined the CTA expression in MM cell lines, and primary myeloma cells in patients with MM. Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to detect the mRNA expression of MAGE-C1/CT7, SSX1, SSX2 and SSX4 in MM cell lines of RPMI-8226 and U266, and bone marrow (BM) cells of 25 MM patients and 18 healthy volunteers. The results showed that the 4 CTAs were expressed in RPMI-8226 and U266 cell lines. The positive expression rate of MAGE-C1/CT7, SSX1, SSX2 and SSX4 in the BM cells of 25 MM patients was 28% (7/25), 80% (20/25), 40% (10/25) and 68% (17/25), respectively. In contrast, the expression of any member of the CTAs was not detected in BM cells of 18 healthy volunteers. The expression of two or more CTAs was detected in 80% (20/25) MM patients, and that of at least one CTA in 88% (22/25). The mRNA expression levels of SSX1 and SSX4 were significantly higher in patients with MM at stage III than in those at stage I and II (P<0.05). No statistically significant differences were observed in the mRNA expression levels of MAGE-C1/CT7 and SSX2 in further stratified analyses by age, gender, MM types and percentage of MM cells in BM (P>0.05). In conclusion, our present study showed that MAGE-C1/CT7, SSX1, SSX2 and SSX4 were co-expressed in MM cell lines and the primary myeloma cells in MM patients, but not expressed in BM cells of healthy subjects. The mRNA levels of SSX1 and SSX4 are associated with MM clinical stage. This work may provide a new insight into MM immunotherapy in the future.

References

[1] KyleRA, RajkumarSV. Multiple myeloma. N Engl J Med, 2004, 351(18): 1860-1873

[2] RajkumarSV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol, 2012, 87(1): 78-88

[3] PhilipsS, MeniasC, VikramR, et al.. Abdominal manifestations of extraosseous myeloma: cross-sectional imaging spectrum. J Comput Assist Tomogr, 2012, 36(2): 207-212

[4] ChoHJ, CaballeroOL, GnjaticS, et al.. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NYESO-1 (CT6). Cancer Immun, 2006, 6: 12

[5] RajagopalanK, MooneySM, ParekhN, et al.. A majority of the cancer/testis antigens are intrinsically disordered proteins. J Cell Biochem, 2011, 112(11): 3256-3267

[6] CaballeroOL, ZhaoQ, RimoldiD, et al.. Frequent MAGE mutations in human melanoma. PLoS One, 2010, 5(9): e12773

[7] Curioni-FontecedroA, NuberN, Mihic-ProbstD, et al.. Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. PLoS One, 2011, 6(6): e21418

[8] CostaFF, BlancKL, BrodinB. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells, 2007, 25(3): 707-711

[9] JungbluthAA, ElyS, DilibertoM, et al.. The cancer-testis antigens CT7 (MAGEC1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood, 2005, 106(1): 167-174

[10] de CarvalhoF, CostaET, CamargoAA, et al.. Targeting MAGE-C1/CT7 expression increases cells sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines. PLoS One, 2011, 6(11): e27707

[11] AtanackovicD, HildebrandtY, JadczakA, et al.. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica, 2010, 95(5): 785-793

[12] AtanackovicD, LuetkensT, HildebrandtY, et al.. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res, 2009, 15(4): 1343-1352

[13] SmithHA, McNeelDG. The SSX family of cancer-test is antigens as target proteins for tumor therapy. Clin Dev Immunol, 2010, 2010: 150 591

[14] TaylorBJ, ReimanT, PittmanJA, et al.. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J Immunother, 2005, 28(6): 564-575

[15] de CarvalhoF, VettoreAL, ColleoniGW. Cancer/testis antigen MAGE-C1/CT7: new target for multiple myeloma therapy. Clin Dev Immunol, 2012, 2012: 257 695

[16] KimR, KulkarniP, HannenhalliS. Derepression of cancer/testis antigens in cancer is associated with distinct patterns of DNA hypomethylation. BMC Cancer, 2013, 13: 144

[17] HudolinT, KastelanZ, IlicI, et al.. Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma. J Transl Med, 2013, 11: 123

[18] van der BruggenP, TraversariC, ChomezP, et al.. A gene encoding an antigen recognized bycytolytic T lymphocytes on a human melanoma. Science, 1991, 254(5038): 1643-1647

[19] de CarvalhoF, AlvesVL, BragaWM, et al.. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. Cancer Immunol Immunother, 2013, 62(1): 191-195

[20] AtanackovicD, LuetkensT, HildebrandtY, et al.. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res, 2009, 15(4): 1343-1352

[21] AndradeVC, VettoreAL, FelixRS, et al.. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun, 2008, 8: 2

[22] NakaN, JoyamaS, TsukamotoY, et al.. Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification. J Mol Diagn, 2005, 7(2): 187-197

[23] ZhangY, BaoL, ChenH, et al.. Expression level of MAGE-C1/CT7 gene in bone marrow cells with multiple myeloma by real-time quantitative PCR. Ch Chin J Clin (Chinese), 2011, 5(10): 2839-28

[24] AkersSN, OdunsiK, KarpfAR. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol, 2010, 6(5): 717-732

RIGHTS & PERMISSIONS

Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg